Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is expected to continue seeing strong demand for its robotic surgical systems, leading to continued top and bottom-line growth. The company's strong market position, growing ecosystem, and increasing value offered to customers should drive further adoption. Additionally, the company's new product launches, such as the next-generation DV5 system and the SP stapler, are expected to contribute to future growth. Despite some near-term margin compression due to tariff dynamics, the company's long-term outlook remains positive.

Intuitive Surgical is facing various risks, including the negative impacts of COVID-19 on the healthcare system, slower adoption of new products, declining procedure volumes, increased competition in the robotic market, and delays in new product approvals. The company has a premium valuation compared to its peers, with a target EV/EBITDA multiple of ~32x in 2027. While Intuitive's recent results have been solid, the company's guidance for the future lacks clarity and its stock has been underperforming. There are concerns about the company's structural headwinds and the potential for a deterioration of demand. However, the company remains dominant in its market with a strong position, and has opportunities for growth in areas such as cardiac and gastrointestinal procedures. The company has also submitted a new product for FDA clearance and has plans to launch an Extended Use Program that could help with penetration and compete with emerging players in the market. Despite the positive updates, the stock's performance and the lack of certainty in its guidance may give cause for concern about the company's long-term outlook.